ArticleMolecular genetics and genomics : MGG2026
A combined computational and functional approach identifies FBLN5 as an amino acid metabolism-related gene and suppressing colorectal cancer progression.
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fibulin-5 (FBLN5) as a context-dependent pan-cancer regulator: integrated multi-omics analysis reveals dual roles in tumor progression and therapeutic resistance.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The importance of amino acid metabolism in regulating cancers progression was investigated by accumulating research. But the role of amino acid metabolism-related genes (AAMRGs) played in the colorectal cancer (CRC) progression remains unclear. We used Cox-LASSO analysis to construct an AAMRG prognostic signature and performed Gene set enrichment analysis (GSEA) for further investigation. Moreover, RT‒qPCR was adopted to estimate the expression of AAMRGs in clinical samples. Cell-based assays, including CCK-8, colony formation, and transwell assays were also performed to identify the roles of fibulin 5 (FBLN5) in CRC progression. We established a 10-AAMRG prognostic signature and stratified CRC samples into two risk groups, which showed significant differences in immune infiltration and EMT. RT-qPCR and human protein atlas data confirmed the mRNA and protein expression of these 10 AAMRGs, validating our bioinformatics findings. Importantly, functional assays revealed that FBLN5 overexpression suppressed CRC cell proliferation, migration, and invasion in vitro, as well as tumor growth in vivo. Our study establishes a novel 10-AAMRG signature as a promising predictor of therapeutic response and prognosis in CRC, and we identify FBLN5 as a pivotal protective factor in CRC progression, offering potential therapeutic value for targeted interventions.
Indexed as
Identifiers
41618991What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.